Organization (Academic)
Hiroshima University
ClinicalTrials.gov lists Hiroshima University as lead sponsor of 45 trials. It has 2 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 6 registered with a 2026 start date. The dashed outline is the pace from the 6 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo HU, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Hiroshima University: 45 lead-sponsored trials and 1 legal-entity registration.
Disease areas (39)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Stroke | 8 |
| Diabetes Mellitus | 5 |
| Dyslipidemias | 4 |
| Hyperlipidemias | 4 |
| Ischemic Stroke | 4 |
Showing 5 of 39 disease areas.
Trials by start year as sponsor or collaborator (18)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 6 |
| 2025 | 4 |
| 2024 | 5 |
| 2023 | 3 |
| 2022 | 3 |
| 2021 | 2 |
| 2020 | 1 |
| 2019 | 3 |
| 2018 | 2 |
| 2014 | 4 |
Showing 10 of 18 years.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (2)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| 0,9% Chloride Sodium | 1 |
| AMINOLEVULINIC ACID HYDROCHLORIDE | 1 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 73% hit target (n=11) | 50% on time (n=12) |
Journals published in (61)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Stroke | 6 |
| BMJ open | 5 |
| JMIR research protocols | 4 |
| PloS one | 3 |
| Journal of medical Internet research | 2 |
Showing 5 of 61 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 215 | 44 | 2025-09-30 |
Organization relationships (9)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Ministry of Health, Labour and Welfare, Japan | Co sponsors trial with | 3 |
| Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | Co sponsors trial with | 3 |
| North South University, Bangladesh | Co sponsors trial with | 2 |
| Complejo Hospitalario de Especialidades Juan Ramón Jimenez | Co sponsors trial with | 1 |
| Tokushima University | Co sponsors trial with | 1 |
Showing 5 of 9 relationships.
Latest dated events (269)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-09 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04-20 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-02-15 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-02-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-02-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 269 events.
Biomarker capability evidence (16)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| BSN | Trial sponsor | Named in trial inclusion criteria |
| EBP | Trial sponsor | Named in trial inclusion criteria |
| EBP | Trial sponsor | Named in trial inclusion criteria |
| GPT2 | Trial collaborator | Named in trial inclusion criteria |
| SETX | Trial collaborator | Named in trial inclusion criteria |
Showing 5 of 16 evidence rows.
Biomarkers this organization publishes on (374)
Shown in this order: most publications first.
Showing 5 of 374 biomarkers.
On Scientist.com
Hiroshima University is listed as a research supplier in the Scientist.com network.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, and clia clinical laboratory certificates.
Work with Hiroshima University on Scientist.com
For prices, more details, or to contact Hiroshima University, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.